RxSight, Inc. (NASDAQ:RXST - Get Free Report) insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $49.78, for a total value of $154,318.00. Following the sale, the insider now owns 42,246 shares of the company's stock, valued at approximately $2,103,005.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ilya Goldshleger also recently made the following trade(s):
RXST stock traded up $0.44 during midday trading on Friday, reaching $50.47. 363,912 shares of the company's stock traded hands, compared to its average volume of 473,295. The company has a 50-day simple moving average of $52.13 and a two-hundred day simple moving average of $53.82. RxSight, Inc. has a 1-year low of $20.66 and a 1-year high of $66.54. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -49.48 and a beta of 1.20.
RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm had revenue of $34.89 million during the quarter, compared to analysts' expectations of $32.33 million. During the same period last year, the firm posted ($0.40) EPS. The business's revenue was up 67.6% on a year-over-year basis. Equities research analysts forecast that RxSight, Inc. will post -0.81 EPS for the current year.
Several equities analysts have commented on RXST shares. BTIG Research upped their price target on RxSight from $72.00 to $73.00 and gave the company a "buy" rating in a report on Monday, July 15th. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a report on Tuesday, August 6th. Oppenheimer dropped their target price on RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a report on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Finally, Stifel Nicolaus dropped their target price on RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $60.14.
View Our Latest Research Report on RxSight
A number of hedge funds and other institutional investors have recently bought and sold shares of RXST. Marshall Wace LLP acquired a new stake in RxSight during the 2nd quarter valued at $19,512,000. Driehaus Capital Management LLC increased its stake in shares of RxSight by 74.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company's stock valued at $42,490,000 after buying an additional 302,367 shares during the period. Baillie Gifford & Co. raised its position in shares of RxSight by 438.8% during the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company's stock worth $21,554,000 after acquiring an additional 291,733 shares during the last quarter. William Blair Investment Management LLC acquired a new position in shares of RxSight during the second quarter valued at $14,942,000. Finally, M&G Plc bought a new position in RxSight in the first quarter valued at about $7,354,000. 78.78% of the stock is owned by institutional investors and hedge funds.
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.